Back to Search
Start Over
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
- Source :
-
Journal of Immunology Research . 10/11/2015, Vol. 2015, p1-8. 8p. 2 Charts, 2 Graphs. - Publication Year :
- 2015
-
Abstract
- Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus- (HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-matched peptides were selected based on the preexisting IgG responses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35-44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks. Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination. Results. Forty-two patients were enrolled. Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted. Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination. Peptide-specific IgG responses were also boosted in 19 of 36 patients. Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival. Conclusion. Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LIVER cancer
*HEPATITIS C vaccines
*LIVER cancer patients
*IMMUNE response
*MEDICATION safety
*HEPATITIS C diagnosis
*TUMOR treatment
*CLINICAL trials
*COMPARATIVE studies
*HEPATITIS viruses
*IMMUNIZATION
*HEPATOCELLULAR carcinoma
*IMMUNOGLOBULINS
*LIVER tumors
*RESEARCH methodology
*MEDICAL cooperation
*MEDICAL protocols
*RESEARCH
*SURVIVAL analysis (Biometry)
*T cells
*TUMOR antigens
*VACCINES
*VIRAL antigens
*EVALUATION research
*CANCER vaccines
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 23148861
- Volume :
- 2015
- Database :
- Academic Search Index
- Journal :
- Journal of Immunology Research
- Publication Type :
- Academic Journal
- Accession number :
- 110561808
- Full Text :
- https://doi.org/10.1155/2015/473909